We are international
Donate
TEXT SIZE   
   back

ASH 2011: Dr. Richardson - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
12.07.11

Be the first to comment

 related articles